482308-04-3

Basic information

• Product Name: 1-(4-AMINO-PHENYL)-PIPERIDINE-2-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: 1-(4-AMINO-PHENYL)-PIPERIDINE-2-CARBOXYLIC ACID ETHYL ESTER
• CAS NO: 482308-04-3
• Molecular Formula: C₁₄H₂₀N₂O₂
• Molecular Weight: 248.32
• Product Categories: pharmacetical
• Mol File: 482308-04-3.mol

Chemical Properties

• Boiling Point: 410.7°C at 760 mmHg
• Flash Point: 202.2°C
• Appearance: /
• Density: 1.138g/cm³
• Vapor Pressure: 5.89E-07mmHg at 25°C
• Refractive Index: 1.563
• CAS DataBase Reference: 1-(4-AMINO-PHENYL)-PIPERIDINE-2-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-AMINO-PHENYL)-PIPERIDINE-2-CARBOXYLIC ACID ETHYL ESTER(482308-04-3)
• EPA Substance Registry System: 1-(4-AMINO-PHENYL)-PIPERIDINE-2-CARBOXYLIC ACID ETHYL ESTER(482308-04-3)

Safety Data

• Hazardous Substances Data: 482308-04-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-AMINO-PHENYL)-PIPERIDINE-2-CARBOXYLIC ACID ETHYL ESTER is used as a chemical intermediate for the synthesis of various drugs and pharmaceuticals. Its unique structural features make it a promising candidate for the development of new medications.
Used in Drug Synthesis:
1-(4-AMINO-PHENYL)-PIPERIDINE-2-CARBOXYLIC ACID ETHYL ESTER is used as a building block in the creation of novel drug molecules. Its structural properties allow for the development of compounds with potential therapeutic applications.
Used in Research and Development:
1-(4-AMINO-PHENYL)-PIPERIDINE-2-CARBOXYLIC ACID ETHYL ESTER is used as a research compound for studying its pharmacological activities and potential therapeutic properties. This can lead to the discovery of new drugs and treatments for various medical conditions.

InChI:InChI=1/C14H20N2O2/c1-2-18-14(17)13-5-3-4-10-16(13)12-8-6-11(15)7-9-12/h6-9,13H,2-5,10,15H2,1H3

Upstream product

• 927701-04-0 ethyl 1-(4-nitrophenyl)piperidine-2-carboxylate 
• 15862-72-3 ethyl pipecolate 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 1444001-40-4 ethyl 1-(4-((S)-5-((2-((tert-butoxycarbonyl)amino)thiazole-5-carboxamido)methyl)-2-oxooxazolidin-3-yl)phenyl)piperidine-2-carboxylate 
• 1444001-25-5 ethyl 1-(4-(((S)-3-(1,3-dioxoisoindolin-2-yl)-2-hydroxypropyl)amino)phenyl)piperidine-2-carboxylate 

Relevant articles and documents

Transformation of a selective factor Xa inhibitor rivaroxaban into a dual factor Xa/thrombin inhibitor by modification of the morpholin-3-one moiety

Replacement of the P4 morpholin-3-one moiety in a selective factor Xa inhibitor rivaroxaban by 2-ethoxycarbonylpiperidine resulted in a dual factor Xa/thrombin inhibitor 24, possessing a Ki of 62 ± 18 nM for factor Xa and a Ki/

Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores

Dual antithrombotic agents acting as anticoagulants and aggregation inhibitors could have substantial advantages over currently prescribed combinations of antithrombotic drugs. Herein, we report compounds with moderate inhibitory activity for factor Xa an

COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES

The present invention relates to combinations of A) oxazolidinones of the formula (I) with B) acetylsalicylic acid (aspirin) and C) an ADP receptor antagonist, in particular P2Y12 purinoreceptor blocker, to a process for producing these combinations and to the use thereof as medicaments, in particular for the prophylaxis and/or treatment of thromboembolic disorders.

MICROANGIOPATHY TREATMENT AND PREVENTION

The present invention relates to the use of selective factor Xa inhibitors, in particular of oxazolidinones of the formula (I) for the treatment and/or prophylaxis of microangiopathies and also their use for the production of medicaments for the treatment and/or prophylaxis of microangiopathies.

Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders

The present invention relates to combinations of A) oxazolidinones of the formula (I), with B) antiarrhythmics, processes for the production of these combinations, their use for the prophylaxis and/or treatment of diseases, and their use for the manufacture of medicaments for the prophylaxis and/or treatment of diseases, especially of thromboembolic disorders and/or complications.

Substituted oxazolidinones and their in the field of blood coagulation

The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.